Companies › SyneuRx International (Taiwan)
1 active drug program in 1 registered trial: 1 Phase 2; Psychiatry; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NaBen® NMDA receptor modulator (GRIN2B antagonist) | GRIN2B | Phase 2 | Refractory Schizophrenia | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03094429 | NaBen® | Phase 2 | Refractory Schizophrenia | Psychiatry | Dec 2026 |
Praxis Precision Medicines Syndeio Biosciences GRIN Therapeutics SHINKEI Therapeutics Aptinyx Neuren Pharmaceuticals BnH Research Johnson & Johnson (Janssen)
atai Therapeutics Arialys Australia Syndeio Biosciences Draig Therapeutics Kadence Bio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.